Trial Profile
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- Acronyms Alliance
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results of an analysis assessing genetic predictors of sorafenib-induced toxicities from two clinical studies: ALLIANCE and TARGET presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 17 Jan 2021 Results assesing radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma by using data from this study presented at the 2021 Gastrointestinal Cancers Symposium.